Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 286, Kate Estep, Flatiron Health

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

R&D

Life sciences real estate: Beyond labs

Growth in biotechnology, pharmaceutical R&D, and advanced therapies is driving demand for specialist laboratory space.

R&D

Inspection readiness is now a commercial question

Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

Views & Analysis

Simple steps to better communicate NHS medicines spend

Leela Barham says that there’s a communication problem when it comes to one of the most important and basic statistics about medicines in the UK: how much the UK spends on them.

Views & Analysis

Is Tecfidera’s patent win a pyrrhic victory for Biogen?

Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a patent challenge – but will the boost mean much when the company still fac

Views & Analysis

What HCPs think about pharma

For a long time, I have been observing how healthcare professionals (HCPs) are talking about the pharmaceutical industry – including their conversations about how the pharmaceutical industr

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.